| Literature DB >> 35513806 |
Abeer A Khamis1, Rana M Ibrahim2, Gad B El-Hefnawy3, Wafaa M Ibrahim4, Ehab M Ali3,5.
Abstract
BACKGROUND: Genetic instability leads to genome mutations, changes in nucleotide sequences, rearrangements, and gains or losses of part of the chromosomes. This instability can initiate and develop cancer. This study evaluated genomic stability in methotrexate and anthocyanin-treated mammary adenocarcinoma model. Seventy albino mice were divided into seven groups: negative control, anthocyanin, methotrexate, Ehrlich's solid tumor; Ehrlich's solid tumor and methotrexate; Ehrlich's solid tumor and anthocyanin; and Ehrlich's solid tumor, methotrexate, and anthocyanin groups.Entities:
Keywords: Antitumor drug; DNA damage; Detoxifying enzyme; Ehrlich’s solid tumor; Flavonoids; Poly[adenosine diphosphate (ADP)-ribose] polymerase
Year: 2022 PMID: 35513806 PMCID: PMC9074366 DOI: 10.1186/s12263-022-00709-8
Source DB: PubMed Journal: Genes Nutr ISSN: 1555-8932 Impact factor: 4.423
Tumor volume (cm3) and tumor weight (g) in groups IV, V, VI, and VII
| Groups | Tumor volume (cm | Tumor weight (g) |
|---|---|---|
| | 0.83-5.1 | 0.13-2.74 |
| | 2±0.45 | 1.12±0.14 |
| | 0.15-2.94 | 0.05-0.45 |
| | 1.2±0.34 | 0.26±0.018 |
| | < 0.01 ↓ | <0.001 ↓ |
| | -40% | -77% |
| | 0.28-3.2 | 0.1-0.89 |
| | 1.4±0.26 ↓ | 0.47±0.035 |
| | < 0.01 | <0.001 ↓ |
| | N.S | <0.001 ↑ |
| | -30% | -58% |
| | 0.15-1.88 | 0.11-0.40 |
| | 0.7±0.09 | 0.25±0.01 |
| | < 0.001 ↓ | <0.001 ↓ |
| | < 0.01 ↓ | N.S. |
| | < 0.01 ↓ | <0.01 ↓ |
| | −65% | −78% |
p versus EST, p versus EST and MTX , p versus EST and ACs, Significant p < 0.05, NS not significant
Determination of serum ALT and AST activities (unit/mL), creatinine and urea levels (mg/dL), and arylesterase activity (nmol/min/mL) in the different groups
| Groups | ALT Unit/ml | AST Unit/ml | Creatinine mg/dl | Urea mg/dl | Arylesterase nmole/min/ml |
|---|---|---|---|---|---|
| | 37–42 | 63–75 | 0.49–0.59 | 38–42 | 494.12–528.82 |
| | 39.2±1.9 | 68.4±4.7 | 0.54±0.04 | 40±1.6 | 522.79±17.68 |
| | 34–39 | 22–34 | 0.41–0.57 | 30–39 | 468.24–582.35 |
| | 36.6±2.1 | 28±4.7 | 0.5±0.07 | 35.2±3.6 | 530.26±43.04 |
| | N.S. | ↓< 0.01 | N.S. | N.S. | N.S. |
| | –6.6% | –83.4% | –7.4% | –12% | 1.43% |
| | 215–265 | 224–296 | 0.60–0.98 | 55–65 | 210.59–258.82 |
| | 244.4±22.3 | 252.4±29.4 | 0.79±0.18 | 59±3.9 | 239.41±18.76 |
| | ↑< 0.001 | ↑< 0.001 | N.S. | ↑< 0.001 | ↓< 0.001 |
| | 523.5% | 49.88% | 46.29% | 47.5% | -59.72% |
| | 49–54 | 600–676 | 0.55–0.67 | 86–90 | 120–135 |
| | 51.6±2.1 | 628.2±29.6↑< | 0.6±0.05 | 88±1.6 | 127.6±5.94 |
| | N.S. | 0.001 | N.S. | ↑< 0.001 | ↓< 0.001 |
| | 31.6% | 273% | 11.11% | 120% | -75.59% |
| | 48–57 | 919–980 | 0.86–1.98 | 48–57 | 262.35–290.58 |
| | 52.2±3.8 | 945.6±24.1 | 1.34±0.47 | 51.2±3.6 | 274.99±10.17 |
| | N.S. | ↑< 0.001 | ↑< 0.001 | ↑< 0.001 | ↓< 0.001 |
| | N.S. | ↑< 0.001 | ↓< 0.001 | ↓< 0.01 | ↑< 0.001 |
| | 33.1% | 461.5% | 148.15% | 28% | -47.39% |
| | 56–65 | 712–853 | 0.55–0.60 | 35–47 | 254.12–289.41 |
| | 61.6±3.6 | 810.6±56.2 | 0.57±0.02 | 41.8±4.5 | 270.79±12.88 |
| | ↑< 0.01 | ↑< 0.001 | N.S. | N.S. | ↓< 0.001 |
| | N.S. | ↑< 0.001 | N.S. | ↑< 0.001 | ↑< 0.001 |
| | N.S. | ↑< 0.001 | < 0.001 | ↓ < 0.01 | N.S. |
| | 57.14% | 381.4% | 5.5% | 4.5% | –48.20% |
| | 55–59 | 835–980 | 0.24–0.36 | 40–49 | 231.76–288.24 |
| | 56.4±2.1 | 878.6±60.9 | 0.3±0.05 | 43.8±3.9 | 277.08±28.1 |
| | N.S. | ↑< 0.001 | N.S. | N.S. | ↓< 0.001 |
| | N.S. | ↑< 0.001 | N.S. | ↑< 0.001 | ↑< 0.001 |
| | N.S. | N.S. | ↓< 0.01 | ↓< 0.05 | N.S. |
| | N.S. | N.S. | N.S. | N.S. | N.S. |
| | 43.87% | 421.7% | -44.44% | 9.5% | -46.99% |
P versus negative control, P versus EST, P versus EST and MTX, P versus EST and ACs, Significant p < 0.05, NS not significant
Cytoplasmic (GST) (nmol/min/mg protein) activity and fragmented DNA in groups IV, V, VI, and VII
| Groups | GST nmol/min/mg protein | PARP Unit/mg protein | Fragmented DNA % |
|---|---|---|---|
| | 47.5-53.70 | 0.01-0.06 | 17.5-27.86 |
| | 50.1±2.6 | 0.04±0.02 | 23.09±3.2 |
| | 12.24-28.33 | 0.04-0.11 | 26.17-33.52 |
| | 19.3±5.8 | 0.08±0.03 | 28.59±2.3 |
| | ↓< 0.001 | N.S. | N.S. |
| | -61.48% | 100% | 23.82% |
| | 25.07–30.15 | 0.07–0.14 | 16.99–28.45 |
| | 28.15±1.9 | 0.09±0.03 | 24.08±4.3 |
| | ↓< 0.001 | ↑< 0.05 | N.S. |
| | ↑< 0.01 | N.S. | N.S. |
| | -43.81% | 125% | 4.3% |
| | 20.00-24.91 | 0.15-0.19 | 20.66-39.92 |
| | 23.05±2.4 | 0.17±0.02 | 30.55±6.7 |
| | ↓< 0.001 | ↑< 0.001 | ↑< 0.05 |
| | N.S. | ↑< 0.001 | N.S. |
| | N.S. | ↑< 0.001 | ↑< 0.05 |
| | -53.99% | 325% | 32.3% |
P versus EST, P versus EST and MTX, P versus EST and ACs, Significant p < 0.05 , NS not significant
Fig. 1Poly(ADP-ribose) polymerase (PARP) activity in the different studied groups, where *p < 0.05 versus group IV; ***p < 0.001 versus group IV; ###p < 0.001 versus group V
Genomic instability of the studied groups
| Group IV | Group V | Group VI | Group VII | |
|---|---|---|---|---|
| 39% | 39% | 35.5% | 35.5% | |
| 61% | 61% | 64.3% | 64.3% |
Fig. 2Genomic instability % of the different studied groups
Fig. 3A Agarose gel electrophoresis of OPA-06 primer in tumor mice. B Agarose gel electrophoresis of OPA-07 primer in tumor mice. C Agarose gel electrophoresis of OPA-08 primer in tumor mice. D Agarose gel electrophoresis of OPB-05 primer in tumor mice. E Agarose gel electrophoresis of OPB-18 primer in tumor mice. F Agarose gel electrophoresis of OPU-16 primer in tumor mice. Random-amplified polymorphic DNA (RAPD) profile generated by primers (lane 1 represents the DNA ladder, lanes 2–4 represent group IV, lanes 5–7 represent group V, lanes 8–10 represent group VI, and lanes 11–13 represent group VII)
Fig. 4Photomicrograph of tumor tissue. A Malignant cells with minimal areas of necrosis in group IV (hematoxylin and eosin (H&E), ×100). B Malignant cells with moderate areas of necrosis in group V (H&E, ×200). C Malignant cells with extensive areas of necrosis in group V (H&E, ×200). D Malignant cells with moderate areas of necrosis in group VI (H&E, ×200). E Malignant cells with extensive areas of necrosis in group VI (H&E ×200). F Malignant cells with diffuse areas of necrosis in group VII (H&E ×200)
Fig. 5Correlations between A PARP and GST activities, B PARP activity and fragmented DNA, and C GST activity and fragmented DNA
| 5′ GGTCCCTGAC 3′ | 41°C | 70 | |
| 5′ GAAACGGGTG 3′ | 36.9°C | 60 | |
| 5′ GTGATCGCAG 3′ | 36.9°C | 60 | |
| 5′ TGCGCCCTTC 3′ | 41°C | 70 | |
| 5′ CCACAGCAGT 3′ | 36.9°C | 60 | |
| 5′ CTGCGCTGGA 3′ | 41°C | 70 |